Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Pharmacyclics Llc patents


Recent patent applications related to Pharmacyclics Llc. Pharmacyclics Llc is listed as an Agent/Assignee. Note: Pharmacyclics Llc may have other listings under different names/spellings. We're not affiliated with Pharmacyclics Llc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pharmacyclics Llc-related inventors


Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds. ... Pharmacyclics Llc

Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Described herein are irreversible btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.. . ... Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Methods of treating fibrosis

Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ack inhibitor (e.g., a btk inhibitor, such as for example an irreversible btk inhibitor, such as for example, ibrutinib).. . ... Pharmacyclics Llc

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk. ... Pharmacyclics Llc

Methods of treating and preventing graft versus host disease

Described herein are methods for treating and preventing graft versus host disease using ack inhibitors. The methods include administering to an individual in need thereof an ack inhibitor such as ibrutinib for treating and preventing graft versus host disease.. ... Pharmacyclics Llc

Solvated forms of a bruton's tyrosine kinase inhibitor

Described herein are solvates of the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the solvates, as well as methods of using the solvates, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

Methods for the treatment of her2 amplified cancer

Described herein are methods and compositions for treating her2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.. ... Pharmacyclics Llc

Tec family kinase inhibitor adjuvant therapy

Described herein are methods and compositions comprising a covalent tec family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.. . ... Pharmacyclics Llc

Purinone compounds as kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk. ... Pharmacyclics Llc

02/08/18 / #20180036313

Use of inhibitors of bruton's tyrosine kinase (btk)

Disclosed herein are methods for treating a cancer comprising: a. Administering a btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. ... Pharmacyclics Llc

02/01/18 / #20180030027

Inhibitors of bruton's tyrosine kinase

Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds. ... Pharmacyclics Llc

02/01/18 / #20180028537

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

01/18/18 / #20180015091

Use of inhibitors of bruton's tyrosine kinase (btk)

Disclosed herein are methods for treating a cancer comprising: a. Administering a btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. ... Pharmacyclics Llc

12/21/17 / #20170362246

Inhibitors of bruton's tyrosine kinase

Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.. ... Pharmacyclics Llc

12/21/17 / #20170360796

Btk inhibitor combinations and dosing regimen

Disclosed herein are methods and combination dosing regimen of administering a combination of a btk inhibitor (e.g. Ibrutinib) and an anti-cd20 therapeutic agent for the treatment of a hematologic malignancy. ... Pharmacyclics Llc

12/14/17 / #20170354655

Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations

Provided are compositions for and methods of treating a b-cell malignancy in a subject in need thereof, by administering to the subject a therapeutically effective amount of a combination comprising an inhibitor of a btk inhibitor and a tlr inhibitor.. . ... Pharmacyclics Llc

11/23/17 / #20170334921

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

11/23/17 / #20170333731

Formulations of histone deacetylase inhibitor and uses thereof

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an hdac inhibitor, or a pharmaceutically acceptable salt thereof, are described.. . ... Pharmacyclics Llc

10/26/17 / #20170305919

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

09/21/17 / #20170266186

Use of inhibitors of bruton's tyrosine kinase (btk)

. . Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible btk inhibitor.. ... Pharmacyclics Llc

09/14/17 / #20170258729

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

08/31/17 / #20170246169

Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Described herein are irreversible btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.. . ... Pharmacyclics Llc

08/10/17 / #20170226112

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

07/27/17 / #20170209462

Btk inhibitor combinations for treating multiple myeloma

Disclosed herein are pharmaceutical combinations, dosing regimen, and methods of administering a combination of a btk inhibitor (e.g., ibrutinib), an immunomodulatory agent, and a steroid for the treatment of a hematologic malignancy.. . ... Pharmacyclics Llc

06/01/17 / #20170151243

Methods for the treatment of her2 amplified cancer

Described herein are methods and compositions for treating her2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.. ... Pharmacyclics Llc

04/13/17 / #20170100404

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

03/23/17 / #20170079981

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.. ... Pharmacyclics Llc

02/23/17 / #20170050970

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk. ... Pharmacyclics Llc

02/09/17 / #20170035762

Use of inhibitors of bruton's tyrosine kinase (btk)

Disclosed herein are methods for treating a cancer comprising: a. Administering a btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. ... Pharmacyclics Llc

02/02/17 / #20170027941

Bruton's tyrosine kinase inhibitor combinations and uses thereof

Disclosed are compositions, methods, and kits for treating a solid tumor comprising co-administering to an individual in need thereof a btk inhibitor and an mtor inhibitor; a taxane, or an egfr inhibitor.. . ... Pharmacyclics Llc

01/19/17 / #20170015671

Inhibitors of bruton's tyrosine kinase

Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk. ... Pharmacyclics Llc

01/12/17 / #20170007611

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk. ... Pharmacyclics Llc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pharmacyclics Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmacyclics Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###